Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 1999
Business Overview: The Company operates in two primary segments: Animal Health Products and Research & Development (R&D). Its core revenue drivers are the "First Defense" and "Kamar Heatmount{TM} Detector" products, serving the U.S. and international dairy and beef industries. The Company shifted its R&D focus in 1998 from human health applications to animal health products to improve profitability.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 1999 | 9 Months Ended Sep 30, 1998 |
|---|---|---|
| Total Revenues | $3,605,907 | $3,308,332 |
| Product Sales | $3,468,079 | $3,109,687 |
| Grant Income | $137,828 | $198,645 |
| Net Profit (Loss) | $396,069 | $(4,923) |
| Operating Income | $472,667 | $56,954 |
| Gross Margin (Product Sales) | 55% | 53% |
| Cash and Equivalents (Sep 30, 1999) | $1,769,132 | $1,538,905 (Dec 31, 1998) |
| Net Working Capital | $2,405,658 | $1,866,222 (Dec 31, 1998) |
| Total Debt (Long-term + Current) | $457,829 | $470,606 (Dec 31, 1998) |
| Stockholders' Equity | $2,643,665 | $2,247,596 (Dec 31, 1998) |
Material Changes vs. Prior Period
- Profitability Turnaround: The Company recorded a net profit of $396,069 for the nine months ended September 30, 1999, compared to a net loss of $4,923 in the same period in 1998. This improvement is attributed to increased product sales and reduced R&D expenses.
- Revenue Growth: Product sales increased by 12% ($358,000) year-over-year. Gross margin on product sales improved from 53% to 55%.
- Expense Reduction: R&D expenses decreased by 19% ($145,000) to $606,000, reflecting a strategic shift away from human health research. General and administrative expenses dropped 26% ($107,000) due to management reorganization.
- Joint Venture Write-down: The Company recorded a non-cash charge of $97,134 related to its equity interest in AgriCell Company, LLC. The investment balance was reduced to zero as of September 30, 1999, due to underperformance in lactoferrin sales linked to financial crises in South Korea and Japan.
- Liquidity Improvement: Cash and cash equivalents increased by $230,227 during the period, driven by positive operating cash flows of $247,182.
Guidance, Outlook, and Risks
- Outlook: Management anticipates recording a profit for the full year ended December 31, 1999, contrasting with the net loss of $103,000 in 1998. The Company believes it has sufficient capital resources to meet working capital requirements for the next twelve months.
- Grant Funding: Approximately $101,000 remains available under a Phase II Small Business Innovation Research grant to fund the DiffGAM{TM} clinical development program.
- Regulatory Risk: Inventory includes approximately $37,000 of raw materials for a product pending regulatory approval. Failure to obtain approval would necessitate a write-off.
- License Milestones: The Company successfully extended the exclusivity of a key third-party license for milk protein purification technology through December 31, 2000, by meeting performance milestones.
- Year 2000 Issue: The Company estimates total costs to address Year 2000 compliance will not exceed $30,000. Most software and hardware modifications were completed or in progress by the third quarter of 1999.
- Debt Obligations: The Company holds a mortgage loan of $457,829 (8.62% interest) with a balloon payment of approximately $392,000 due in 2003. The Company intends to repay the principal at the end of the five-year fixed-rate period or reset the rate.
Investor Verification Checklist
- Regulatory Approval Status: Verify the status of the product associated with the $37,000 raw material inventory to assess potential write-off risks.
- Joint Venture Exposure: Confirm that the AgriCell investment is fully written down and that no further losses will impact the balance sheet.
- Debt Refinancing: Assess the Company's ability to refinance or repay the $392,000 balloon payment due in 2003.
- Customer Concentration: Note that 63% to 74% of product sales come from the U.S. dairy and beef industries; verify stability of these key accounts.
- Grant Dependency: Monitor the utilization of the remaining $101,000 in grant funds and the timeline for the DiffGAM{TM} program.